硬腭鳞状细胞癌患者的预后因素。

Prognostic factors in patients with soft palate squamous cell carcinoma.

机构信息

Radiation Oncology Department, Gustave Roussy Cancer Campus, Paris, France.

INSERM1030, Gustave Roussy Cancer Campus, Paris, France.

出版信息

Head Neck. 2019 May;41(5):1441-1449. doi: 10.1002/hed.25598. Epub 2019 Jan 12.

DOI:10.1002/hed.25598

PMID:30636178

Abstract

BACKGROUND

To define the prognostic factors associated with outcome in patients with soft palate squamous cell carcinoma (SCC).

METHODS

Previously untreated patients with soft palate and uvula SCC treated in our institution between 1997 and 2012 were collected. The prognostic value of clinical, hematological, and treatment characteristics was examined.

RESULTS

We identified 156 patients, median age 58 years, with 71% drinkers, 91% smokers; 19% had synchronous cancer. Front-line treatment was chemoradiotherapy in 58 (37%), radiotherapy alone in 60 (39%), surgery in 17 (11%), and induction chemotherapy in 21 patients (14%). The 5-year actuarial overall survival (OS) and progression-free survival (PFS) were 41% and 37%, respectively. In univariate analysis, T3-T4 vs T1-T2 stage, N2-N3 vs N0-N1 stage, and neutrophil count >7 g/L were associated with worse OS and PFS (P < .05).

CONCLUSION

In patients with soft palate SCC, inflammation biomarkers were associated with OS.

摘要

背景

明确与软腭鳞状细胞癌（SCC）患者预后相关的预测因素。

方法

收集了我院在 1997 年至 2012 年间治疗的未经治疗的软腭和悬雍垂 SCC 患者。检验了临床、血液学和治疗特征的预后价值。

结果

我们共确定了 156 例患者，中位年龄为 58 岁，71%为饮酒者，91%为吸烟者；19%有同步癌症。一线治疗为 58 例（37%）放化疗，60 例（39%）单纯放疗，17 例（11%）手术，21 例（14%）诱导化疗。5 年总生存率（OS）和无进展生存率（PFS）分别为 41%和 37%。单因素分析显示，T3-T4 期与 T1-T2 期、N2-N3 期与 N0-N1 期以及中性粒细胞计数＞7g/L 与较差的 OS 和 PFS 相关（P＜0.05）。